
Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
---|---|---|---|---|---|
COO
The Cooper Companies
|
$995.2M | $0.93 | 6.1% | 105.39% | $92.09 |
BSX
Boston Scientific
|
$4.9B | $0.73 | 18.78% | 229.3% | $117.36 |
KIDS
OrthoPediatrics
|
$61.4M | -$0.28 | 16.28% | -7.69% | $36.71 |
LUCY
Innovative Eyewear
|
$1M | -$0.77 | 223.96% | -58.82% | $7.00 |
NXGL
NexGel
|
$3.1M | -$0.07 | 113.89% | -50% | $6.00 |
STAA
Staar Surgical
|
$40.9M | -$0.56 | -58.72% | -760% | $19.20 |
Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
---|---|---|---|---|---|---|---|
COO
The Cooper Companies
|
$72.70 | $92.09 | $14.5B | 35.29x | $0.01 | 0% | 3.66x |
BSX
Boston Scientific
|
$103.19 | $117.36 | $152.7B | 75.32x | $0.00 | 0% | 8.75x |
KIDS
OrthoPediatrics
|
$22.56 | $36.71 | $558.8M | -- | $0.00 | 0% | 2.46x |
LUCY
Innovative Eyewear
|
$2.17 | $7.00 | $8.3M | -- | $0.00 | 0% | 2.44x |
NXGL
NexGel
|
$2.41 | $6.00 | $18.4M | -- | $0.00 | 0% | 1.63x |
STAA
Staar Surgical
|
$17.09 | $19.20 | $846.4M | 49.73x | $0.00 | 0% | 3.03x |
Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
---|---|---|---|---|
COO
The Cooper Companies
|
23.76% | 0.582 | 15.85% | 0.89x |
BSX
Boston Scientific
|
33.49% | 0.780 | 7.48% | 0.68x |
KIDS
OrthoPediatrics
|
17.41% | 0.247 | 11.97% | 2.74x |
LUCY
Innovative Eyewear
|
-- | 4.943 | -- | 11.96x |
NXGL
NexGel
|
11.28% | -0.559 | 2.86% | 0.84x |
STAA
Staar Surgical
|
-- | 0.847 | -- | 3.88x |
Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
---|---|---|---|---|---|---|
COO
The Cooper Companies
|
$679.1M | $184.8M | 3.89% | 5.15% | 16.83% | $18.1M |
BSX
Boston Scientific
|
$3.2B | $937M | 6.35% | 9.57% | 19.02% | $277M |
KIDS
OrthoPediatrics
|
$38.3M | -$10.9M | -9.9% | -11.21% | -17.82% | -$8.4M |
LUCY
Innovative Eyewear
|
$220.5K | -$1.9M | -97.69% | -97.69% | -418.88% | -$2.4M |
NXGL
NexGel
|
$1.2M | -$777K | -51.9% | -59.55% | -23.41% | -$400K |
STAA
Staar Surgical
|
$28M | -$34.7M | -17.97% | -17.97% | -81.56% | -$7.2M |
Boston Scientific has a net margin of 8.75% compared to The Cooper Companies's net margin of 14.45%. The Cooper Companies's return on equity of 5.15% beat Boston Scientific's return on equity of 9.57%.
Company | Gross Margin | Earnings Per Share | Invested Capital |
---|---|---|---|
COO
The Cooper Companies
|
67.75% | $0.44 | $10.9B |
BSX
Boston Scientific
|
68.84% | $0.45 | $33.6B |
The Cooper Companies has a consensus price target of $92.09, signalling upside risk potential of 26.67%. On the other hand Boston Scientific has an analysts' consensus of $117.36 which suggests that it could grow by 13.74%. Given that The Cooper Companies has higher upside potential than Boston Scientific, analysts believe The Cooper Companies is more attractive than Boston Scientific.
Company | Buy Ratings | Hold Ratings | Sell Ratings |
---|---|---|---|
COO
The Cooper Companies
|
8 | 7 | 0 |
BSX
Boston Scientific
|
23 | 2 | 0 |
The Cooper Companies has a beta of 0.985, which suggesting that the stock is 1.451% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.679, suggesting its less volatile than the S&P 500 by 32.134%.
The Cooper Companies has a quarterly dividend of $0.01 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Cooper Companies pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.
The Cooper Companies quarterly revenues are $1B, which are smaller than Boston Scientific quarterly revenues of $4.7B. The Cooper Companies's net income of $87.7M is lower than Boston Scientific's net income of $674M. Notably, The Cooper Companies's price-to-earnings ratio is 35.29x while Boston Scientific's PE ratio is 75.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Cooper Companies is 3.66x versus 8.75x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.
Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
---|---|---|---|---|
COO
The Cooper Companies
|
3.66x | 35.29x | $1B | $87.7M |
BSX
Boston Scientific
|
8.75x | 75.32x | $4.7B | $674M |
OrthoPediatrics has a net margin of 8.75% compared to The Cooper Companies's net margin of -20.34%. The Cooper Companies's return on equity of 5.15% beat OrthoPediatrics's return on equity of -11.21%.
Company | Gross Margin | Earnings Per Share | Invested Capital |
---|---|---|---|
COO
The Cooper Companies
|
67.75% | $0.44 | $10.9B |
KIDS
OrthoPediatrics
|
73% | -$0.46 | $420.3M |
The Cooper Companies has a consensus price target of $92.09, signalling upside risk potential of 26.67%. On the other hand OrthoPediatrics has an analysts' consensus of $36.71 which suggests that it could grow by 62.74%. Given that OrthoPediatrics has higher upside potential than The Cooper Companies, analysts believe OrthoPediatrics is more attractive than The Cooper Companies.
Company | Buy Ratings | Hold Ratings | Sell Ratings |
---|---|---|---|
COO
The Cooper Companies
|
8 | 7 | 0 |
KIDS
OrthoPediatrics
|
3 | 1 | 0 |
The Cooper Companies has a beta of 0.985, which suggesting that the stock is 1.451% less volatile than S&P 500. In comparison OrthoPediatrics has a beta of 1.098, suggesting its more volatile than the S&P 500 by 9.802%.
The Cooper Companies has a quarterly dividend of $0.01 per share corresponding to a yield of 0%. OrthoPediatrics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Cooper Companies pays -- of its earnings as a dividend. OrthoPediatrics pays out -- of its earnings as a dividend.
The Cooper Companies quarterly revenues are $1B, which are larger than OrthoPediatrics quarterly revenues of $52.4M. The Cooper Companies's net income of $87.7M is higher than OrthoPediatrics's net income of -$10.7M. Notably, The Cooper Companies's price-to-earnings ratio is 35.29x while OrthoPediatrics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Cooper Companies is 3.66x versus 2.46x for OrthoPediatrics. Usually stocks with elevated PS ratios are considered overvalued.
Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
---|---|---|---|---|
COO
The Cooper Companies
|
3.66x | 35.29x | $1B | $87.7M |
KIDS
OrthoPediatrics
|
2.46x | -- | $52.4M | -$10.7M |
Innovative Eyewear has a net margin of 8.75% compared to The Cooper Companies's net margin of -391.35%. The Cooper Companies's return on equity of 5.15% beat Innovative Eyewear's return on equity of -97.69%.
Company | Gross Margin | Earnings Per Share | Invested Capital |
---|---|---|---|
COO
The Cooper Companies
|
67.75% | $0.44 | $10.9B |
LUCY
Innovative Eyewear
|
48.52% | -$0.72 | $7.5M |
The Cooper Companies has a consensus price target of $92.09, signalling upside risk potential of 26.67%. On the other hand Innovative Eyewear has an analysts' consensus of $7.00 which suggests that it could grow by 222.58%. Given that Innovative Eyewear has higher upside potential than The Cooper Companies, analysts believe Innovative Eyewear is more attractive than The Cooper Companies.
Company | Buy Ratings | Hold Ratings | Sell Ratings |
---|---|---|---|
COO
The Cooper Companies
|
8 | 7 | 0 |
LUCY
Innovative Eyewear
|
0 | 0 | 0 |
The Cooper Companies has a beta of 0.985, which suggesting that the stock is 1.451% less volatile than S&P 500. In comparison Innovative Eyewear has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
The Cooper Companies has a quarterly dividend of $0.01 per share corresponding to a yield of 0%. Innovative Eyewear offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Cooper Companies pays -- of its earnings as a dividend. Innovative Eyewear pays out -- of its earnings as a dividend.
The Cooper Companies quarterly revenues are $1B, which are larger than Innovative Eyewear quarterly revenues of $454.5K. The Cooper Companies's net income of $87.7M is higher than Innovative Eyewear's net income of -$1.8M. Notably, The Cooper Companies's price-to-earnings ratio is 35.29x while Innovative Eyewear's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Cooper Companies is 3.66x versus 2.44x for Innovative Eyewear. Usually stocks with elevated PS ratios are considered overvalued.
Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
---|---|---|---|---|
COO
The Cooper Companies
|
3.66x | 35.29x | $1B | $87.7M |
LUCY
Innovative Eyewear
|
2.44x | -- | $454.5K | -$1.8M |
NexGel has a net margin of 8.75% compared to The Cooper Companies's net margin of -25.37%. The Cooper Companies's return on equity of 5.15% beat NexGel's return on equity of -59.55%.
Company | Gross Margin | Earnings Per Share | Invested Capital |
---|---|---|---|
COO
The Cooper Companies
|
67.75% | $0.44 | $10.9B |
NXGL
NexGel
|
42.34% | -$0.09 | $6.2M |
The Cooper Companies has a consensus price target of $92.09, signalling upside risk potential of 26.67%. On the other hand NexGel has an analysts' consensus of $6.00 which suggests that it could grow by 148.96%. Given that NexGel has higher upside potential than The Cooper Companies, analysts believe NexGel is more attractive than The Cooper Companies.
Company | Buy Ratings | Hold Ratings | Sell Ratings |
---|---|---|---|
COO
The Cooper Companies
|
8 | 7 | 0 |
NXGL
NexGel
|
0 | 0 | 0 |
The Cooper Companies has a beta of 0.985, which suggesting that the stock is 1.451% less volatile than S&P 500. In comparison NexGel has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
The Cooper Companies has a quarterly dividend of $0.01 per share corresponding to a yield of 0%. NexGel offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Cooper Companies pays -- of its earnings as a dividend. NexGel pays out -- of its earnings as a dividend.
The Cooper Companies quarterly revenues are $1B, which are larger than NexGel quarterly revenues of $2.8M. The Cooper Companies's net income of $87.7M is higher than NexGel's net income of -$712K. Notably, The Cooper Companies's price-to-earnings ratio is 35.29x while NexGel's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Cooper Companies is 3.66x versus 1.63x for NexGel. Usually stocks with elevated PS ratios are considered overvalued.
Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
---|---|---|---|---|
COO
The Cooper Companies
|
3.66x | 35.29x | $1B | $87.7M |
NXGL
NexGel
|
1.63x | -- | $2.8M | -$712K |
Staar Surgical has a net margin of 8.75% compared to The Cooper Companies's net margin of -127.29%. The Cooper Companies's return on equity of 5.15% beat Staar Surgical's return on equity of -17.97%.
Company | Gross Margin | Earnings Per Share | Invested Capital |
---|---|---|---|
COO
The Cooper Companies
|
67.75% | $0.44 | $10.9B |
STAA
Staar Surgical
|
65.76% | -$1.10 | $350M |
The Cooper Companies has a consensus price target of $92.09, signalling upside risk potential of 26.67%. On the other hand Staar Surgical has an analysts' consensus of $19.20 which suggests that it could grow by 12.35%. Given that The Cooper Companies has higher upside potential than Staar Surgical, analysts believe The Cooper Companies is more attractive than Staar Surgical.
Company | Buy Ratings | Hold Ratings | Sell Ratings |
---|---|---|---|
COO
The Cooper Companies
|
8 | 7 | 0 |
STAA
Staar Surgical
|
3 | 9 | 1 |
The Cooper Companies has a beta of 0.985, which suggesting that the stock is 1.451% less volatile than S&P 500. In comparison Staar Surgical has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.753%.
The Cooper Companies has a quarterly dividend of $0.01 per share corresponding to a yield of 0%. Staar Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Cooper Companies pays -- of its earnings as a dividend. Staar Surgical pays out -- of its earnings as a dividend.
The Cooper Companies quarterly revenues are $1B, which are larger than Staar Surgical quarterly revenues of $42.6M. The Cooper Companies's net income of $87.7M is higher than Staar Surgical's net income of -$54.2M. Notably, The Cooper Companies's price-to-earnings ratio is 35.29x while Staar Surgical's PE ratio is 49.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Cooper Companies is 3.66x versus 3.03x for Staar Surgical. Usually stocks with elevated PS ratios are considered overvalued.
Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
---|---|---|---|---|
COO
The Cooper Companies
|
3.66x | 35.29x | $1B | $87.7M |
STAA
Staar Surgical
|
3.03x | 49.73x | $42.6M | -$54.2M |
Signup to receive the latest stock alerts
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Market Cap: $4.2T
P/E Ratio: 58x
Market Cap: $3.8T
P/E Ratio: 43x
Market Cap: $3.1T
P/E Ratio: 35x
SharpLink Gaming [SBET] is down 2.6% over the past day.
Exodus Movement [EXOD] is down 4.14% over the past day.
Unity Software [U] is up 7.51% over the past day.